AI Article Synopsis
- A systematic review and meta-analysis of 18 studies assessed the impact of biologics and small molecules on the risk of COVID-19-related hospitalization in patients with inflammatory bowel disease (IBD).
- Patients with IBD receiving biologic therapies, especially anti-TNFs and ustekinumab, showed a significantly lower risk of hospitalization compared to those not on these treatments.
- In contrast, vedolizumab and tofacitinib did not exhibit a reduced risk of hospitalization, highlighting the varied effects of these medications during the pandemic.
Article Abstract
Background And Aim: The use of biologics and small molecules has been a concern for patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. We aimed to assess the association between the risk of COVID-19-related hospitalization and these agents.
Methods: We made a systematic review and meta-analysis of all published studies from December 2019 to September 2021 to identify studies that reported COVID-19-related hospitalization in IBD patients receiving biologic therapies or tofacitinib. We calculated the risk ratio (RR) to compare the relative risk of COVID-19-related hospitalization in patients receiving these medications to those who were not, at the time of the study.
Results: Eighteen studies were included. The relative risk of hospitalization was significantly lower in patients with IBD and COVID-19 who were receiving biologic therapy (RR = 0.47 [95% confidence interval, CI: 0.42-0.52, < 0.00001]) compared to patients not receiving biologics. The RR was lower in patients receiving anti-tumor necrosis factors (TNFs) compared to those who were not (RR = 0.48 [95% CI: 0.41-0.55, < 0.00001]). A similar finding was observed in patients taking ustekinumab (RR = 0.55 [95% CI: 0.43-0.72, < 0.00001]). Combination therapy involving anti-TNF and an immunomodulator did not lower the risk of COVID-19-related hospitalization (RR = 0.98 [95% CI: 0.82-1.18, = 0.84]). The use of vedolizumab (RR = 1.13 [95% CI: 0.75-1.73, = 0.56]) or tofacitinib (RR = 0.81 [95% CI: 0.49-1.33, = 0.40]) was not associated with a lower risk of COVID-19-related hospitalization.
Conclusion: Regarding COVID-19-related hospitalization in IBD, anti-TNFs and ustekinumab were associated with decreased risk of hospitalization. In addition, vedolizumab and tofacitinib were not associated with COVID-19-related hospitalization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021715 | PMC |
| http://dx.doi.org/10.1002/jgh3.12728 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Federal University of Rio Grande do Sul, Brazil, Porto Alegre, RS, Brazil.
Background: The COVID-19 pandemic is a public health crisis, and its lasting consequences are not yet fully understood. Epidemiological data suggest that low- and middle-income countries, such as Brazil, will bear a considerable burden of COVID-19-related comorbidities. Individuals who have survived COVID-19 often report persistent symptoms, including neurological manifestations such as brain fog.
View Article and Find Full Text PDFIdentification and Validation of Potential Biomarkers and Therapeutic Targets of COVID-19-related Depression.
Comb Chem High Throughput Screen
January 2025
Department of Emergency, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
Background: The prevalence of depression in COVID-19 patients is notably high, disrupting daily life routines and compounding the burden of other chronic health conditions. In addition, to elucidate the connection between COVID-19 and depression, we conducted an analysis of commonly differentially expressed genes [co-DEGs], uncovering potential biomarkers and therapeutic avenues specific to COVID-19-related depression.
Methods: We obtained gene expression profiles from the Gene Expression Omnibus [GEO] database with strategic keyword searches ["COVID-19", "depression," and "SARS"].
Comparison of the effectiveness of awake-prone positioning and high-flow nasal oxygen in patients with COVID-19-related acute respiratory failure between different waves.
Crit Care Sci
January 2025
Intensive Care Department, Hospital Privado de Comunidad - Mar del Plata, Argentina.
Objective: To compare the effectiveness of the awake-prone position on relevant clinical outcomes in patients with COVID-19-related acute respiratory failure requiring high-flow nasal oxygen between different waves in Argentina.
Methods: This multicenter, prospective cohort study included adult patients with COVID-19-related acute respiratory failure requiring high-flow nasal oxygen. The main exposure position was the awake-prone position (≥ 6 hours/day) compared to the non-prone position.
Hypercoagulable Rotational Thromboelastometry During Hospital Stay Is Associated with Post-Discharge DLco Impairment in Patients with COVID-19-Related Pneumonia.
Viruses
December 2024
1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, "Evangelismos" General Hospital, 10676 Athens, Greece.
Hypercoagulation is central to the pathogenesis of acute and post-acute COVID-19. This prospective observational study explored whether rotational thromboelastometry (ROTEM), a method that unveils coagulation status, predicts outcomes of hospitalized patients with COVID-19 pneumonia. We investigated 62 patients using ROTEM that was conducted at enrollment, clinical deterioration, discharge and follow-up visits 1 and 3 months post-discharge.
View Article and Find Full Text PDFAzelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.
Viruses
December 2024
Pharmalex India Pvt. Ltd., Noida 201301, India.
Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentric, phase II clinical trial comparing the rate of hospitalization due to COVID-19 infection between azelastine 0.1% nasal spray and placebo nasal spray treatment groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!